Table S8.
Mean visual acuity and central macular thickness after receiving bevacizumab and photocoagulation for the treatment of diabetic macular edema
| Author | Year | IVB | Photocoagulation | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| n | Mean | SD | n | Mean | SD | ||
| Visual acuity (ETDRS letters) | |||||||
| Faghihi et al30 | 2008 | 42 | 65.0 | 15.0 | 47 | 64.0 | 15.0 |
| Soheilian et al29 | 2009 | 45 | 75.0 | 14.0 | 42 | 70.0 | 20.0 |
| Michaelides et al27 | 2010 | 42 | 61.3 | 10.4 | 38 | 50.0 | 16.6 |
| Solaiman et al31 | 2010 | 21 | 59.0 | 6.0 | 19 | 58.0 | 39.0 |
| USMD (95% CI) | 5.44 (95% CI 0.05 to 10.83) | ||||||
| Central macular thickness (μm) | |||||||
| Faghihi et al30 | 2008 | 42 | 328 | 91 | 47 | 300 | 82 |
| Soheilian et al29 | 2009 | 45 | 317 | 132 | 42 | 290 | 117 |
| Michaelides et al27 | 2010 | 42 | 378 | 134 | 38 | 413 | 135 |
| Solaiman et al31 | 2010 | 21 | 443 | 38 | 19 | 402 | 32 |
| USMD (95% CI) | 23.61 (95% CI –2.78 to 50.00) | ||||||
Abbreviations: CI, confidence interval; IVB, intravitreal bevacizumab; SD, standard deviation; USMD, unstandardized mean difference; ETDRS, Early Treatment Diabetic Retinopathy Study